[1]刘 颖,谢 言,王新天.分子靶向抗肿瘤药物的毒性研究[J].医学信息,2021,34(14):48-50.[doi:10.3969/j.issn.1006-1959.2021.14.013]
　LIU Ying,XIE Yan,WANG Xin-tian.Study on the Toxicity of Molecular Targeted Antitumor Drugs[J].Medical Information,2021,34(14):48-50.[doi:10.3969/j.issn.1006-1959.2021.14.013]
点击复制

分子靶向抗肿瘤药物的毒性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年14期
页码:
48-50
栏目:
综述
出版日期:
2021-07-15

文章信息/Info

Title:
Study on the Toxicity of Molecular Targeted Antitumor Drugs
文章编号:
1006-1959（2021）14-0048-03
作者:
刘 颖; 谢 言; 王新天
（1.天津市药品不良反应监测中心，天津 300191； 2.天津市药品监督管理局，天津 300191）
Author(s):
LIU Ying; XIE Yan; WANG Xin-tian
(1.Tianjin Adverse Drug Reaction Monitoring Center,Tianjin 300191,China; 2.Tianjin Drug Administration,Tianjin 300191,China)
关键词:
分子靶向抗肿瘤药物; 药物毒性; 皮肤毒性
Keywords:
Molecular targeted antitumor drugs; Drug toxicity; Skin toxicity
分类号:
R96
DOI:
10.3969/j.issn.1006-1959.2021.14.013
文献标志码:
A
摘要:
药物是临床治疗肿瘤的主要手段，但是常规化疗药物毒副反应大，临床疗效较不理想。随着医学的发展，多种分子靶向抗肿瘤药物出现，其具有较强的靶向性、疗效性，但分子靶向抗肿瘤药物在临床应用过程中也会出现一些不良反应，会对皮肤、胃肠、心血管、肝等重要脏器造成不同程度损伤，限制了临床的应用和发展。本文就分子靶向抗肿瘤药物的皮肤毒性、心血管毒性、肝毒性及肺毒性作一综述，以期为提出有效预防药物毒性措施及提高分子靶向抗肿瘤治疗提供一定的理论依据。
Abstract:
Drugs are the main method of clinical treatment of tumors, but conventional chemotherapy drugs have serious side effects and the clinical efficacy is not ideal.With the development of medicine, a variety of molecular targeted anti-tumor drugs have appeared, which have strong targeting and curative effects.However, molecular targeted anti-tumor drugs will also have some adverse reactions in the process of clinical application, which will cause varying degrees of damage to important organs such as skin, gastrointestinal, cardiovascular, liver, etc., which limits the clinical application and development.This article reviews the skin toxicity, cardiovascular toxicity, hepatotoxicity and pulmonary toxicity of molecularly targeted antitumor drugs, hoping to provide a theoretical basis for effective prevention of drug toxicity and improvement of molecularly targeted antitumor therapy.

参考文献/References:

[1]鲍明亮,毕清,田青,等.埃克替尼二、三线治疗48 例晚期非小细胞肺癌[J].中国肿瘤,2015,23(3):249-252． [2]杜春霞,陈闪闪,刘潇衍,等.重组人血管内皮抑素联合多西他赛、铂类和氟尿嘧啶类一线治疗进展期胃癌的临床观察[J].临床肿瘤学杂志,2015,19(10):925-928. [3]Li JY,Ren YP,Yuan Y,et al.Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice[J].Acta Pharmacol Sin,2016,37(7):930-940. [4]Singh AP,Shin YG,Shah DK.Application of pharmaco kineticphar macodynamic modeling and simulation for antibody-drug conjugatedevelopment[J].Pharm Res,2015,32(11):3508-3525. [5]巩莉.靶向抗肿瘤药物的不良反应及药学监护[J].山西医药杂志,2017,46(3):347-348. [6]杨万全,王恳,王红,等.消癌平注射液联合吉非替尼治疗晚期肺腺癌的疗效[J].武汉大学学报(医学版),2016,37(5):786-789. [7]张宁.口服靶向抗肿瘤药物的不良反应的观察及预防[J].中国卫生标准管理,2015,6(1):189-190. [8]田春艳,彭仁,白婷婷,等.阿帕替尼不同起始剂量治疗晚期胃癌不良反应及疗效观察[J].实用肿瘤杂志,2018,33(1):66-69. [9]杨宏,韩震,李刚,等.抗血管生成药物引起高血压1例报道[J].肿瘤基础与临床,2017,30(4):367-369. [10]Tanaka H,Takahashi K,Yamaguchi K,et al.Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan[J].Biol Pharm Bull,2018,41(4):644-648. [11]陈惠,王汉萍,张力,等.盐酸埃克替尼一线治疗晚期非小细胞肺癌的疗效与安全性[J].中华内科杂志,2017,56(1):39-43. [12]钱祥云,戈伟.阿帕替尼联合化疗治疗晚期胃癌临床分析[J].中华实用诊断与治疗杂志,2017,31(12):1222-1224. [13]黄平,刘雅娟,陈占红,等.曲妥珠单抗治疗晚期乳腺 癌患者的心脏毒性研究[J].中国临床药理学杂志,2017,33(9):778-781. [14]董雪,李峥.维生素K1乳剂对西妥昔单抗所致皮肤毒性反应的临床疗效研究[J].癌症进展,2015,11(6):587-591,595. [15]陈德连,陈明聪,江会红.大剂量维生素B6联合阿帕替尼治疗晚期非小细胞肺癌的疗效观察[J].浙江医学,2018,40(3):291-293. [16]李保庆,张难,张少为,等.阿帕替尼治疗晚期贲门癌并发高血压的诊断与处理(附1例报告)[J].食管外科电子杂志,2015,3(1):44-45. [17]柳青.厄洛替尼致高龄肺癌患者高血压及心肌缺血1例[J].中华保健医学杂志,2015,17(5):427-428. [18]Jee D,Zako M,La TY.Serum D-dimer levels to evaluate the risk for arterial thromboembolism after intravitreal injection of bevacizumab and ranibizumab[J].J Ocul Pharmacol Ther,2015,31(1):32-36. [19]胡戴,王小溶,伍三兰.盐酸埃克替尼片致双下肢严重水肿1例[J].中国药师,2017,20(5):875-876. [20]蒋梅,郭然.吉非替尼致肝毒性后非小细胞肺癌1例并文献复习[J].癌症进展,2018,16(1):128-130. [21]贾守薇,刘韬,黄红兵.分子靶向抗肿瘤药物的不良反应及其处理对策[J].肿瘤药学,2014,4(1):2-9. [22]邓天霞,张曦,曾东风,等.伊马替尼治疗Ph阳性急性淋巴细胞白血病致全身多发静脉血栓形成1例并文献复习[J].中国输血杂志,2016,29(10):1102-1104. [23]徐玲玲.抗肿瘤血管生成靶向药物的不良反应、发生机制及处理[J].国际肿瘤学杂志,2010,37(3):196-199. [24]李雅,常红莉,王哲,等.吉非替尼靶向治疗中晚期非小细胞肺癌40例[J].现代肿瘤医学,2015,23(20):2959-2961. [25]应晓,王再红,王振华.miR-193b体外协同增强多柔比星对乳腺癌细胞的抗肿瘤效应[J].中国病理生理杂志,2015,31(9):1584-1588.

更新日期/Last Update: 1900-01-01